查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1630982

全球多種癌症早期檢測市場：市場規模、佔有率和趨勢分析（按類型、最終用途、地區和細分市場，2025-2030 年）

Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT & Others), By End Use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

多種癌症早期檢測 (MCED) 市場的成長和趨勢：

根據Grand View Research, Inc.的最新報告，全球多種癌症早期檢測市場規模預計到2030年將達到28.6億美元，2025年至2030年複合年成長率為17%。

需要提供有效的癌症早期檢測方法以便能夠實施適當的治療，以及癌症盛行率的上升和癌症類型的多樣化，預計將推動市場成長。早期檢測和診斷的需求有助於輕鬆管理疾病並降低後續死亡率，從而推動整個市場的發展。

多種癌症早期檢測 (MCED) 測試旨在即使患者無症狀時也能檢測出體內的腫瘤。它會同時評估多種訊號來確定您是否可能患有癌症。目前已開發出多種檢測方法用於早期發現癌症，但 MCED篩檢測試是最近才在美國實用化的首個實驗室開發的測試。例如，2022 年 7 月，GRAIL 的 Galleri 在聖路易斯的 Mercy 以 LDT 的形式開放。此外，Exact Sciences 和 Freenome 正在開發 MCED篩檢測試，而 GRAIL 的 Galleri 測試無需保險即可推廣，據稱可以檢測多達 50 種不同類型的測試。

研究表明，MCED 測試對於檢測疾病的晚期或進展階段比檢測早期階段更為敏感，而早期階段是可以治療，有時甚至可治癒的。此外，該測試具有高度特異性，這意味著沒有癌症的人極不可能檢測出陽性。目前，MCED 的開發研究仍在進行中，以滿足早期診斷的需求。

市場上的領先公司聲稱他們可以識別從兩三種到多達 50 種類型的癌症。公司專注於發展、開發和快速商業化這些篩檢測試。例如，2020 年 12 月，Singlera Genomics 在 B 輪融資中籌集了 1.5 億美元，用於開發、行銷和推廣其 MCED 測試。 GRAIL 與 Point32Health 啟動了先導計畫，使得 Point32Health 成為第一個包含 MCED 測試的商業健康計劃。

多種癌症早期檢測市場：分析概述

  • 基因組、LDT 和其他部分引領市場，到 2024 年將佔據 91.28% 的佔有率。該領域的成長得益於 LDT 不需要 FDA核准即可在診斷實驗室中使用。
  • 預計預測期內液態切片領域將以最快的複合年成長率成長。該細分市場的成長歸因於越來越多的參與者獲得投資者資金用於新測試開發。
  • 2024 年，醫院終端用途領域佔據市場主導地位，佔有率為 48.44%。這是因為人們越來越喜歡醫院治療，因為他們可以在一個地方獲得一系列的服務。
  • 由於醫療保健基礎設施的顯著改善、人口的成長以及越來越多的當地企業進入市場，預計亞太地區多種癌症早期檢測市場將在預測期內實現最快的複合年成長率。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 多種癌症早期檢測 (MCED) 市場：促進因素、趨勢和範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 多種癌症早期檢測 (MCED) 市場分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 多種癌症早期檢測 (MCED) 市場：按類型進行估計和趨勢分析

  • 按類型市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球多種癌症早期檢測 (MCED) 市場展望（按類型）
  • 市場規模預測及趨勢分析（2018-2030年）
  • 液態生物檢體
  • 基因面板、LDT 等

5. 多種癌症早期檢測 (MCED) 市場：按最終用途進行的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球多種癌症早期檢測 (MCED) 市場前景（按最終用途）
  • 市場規模預測及趨勢分析（2018-2030年）
  • 醫院
  • 診斷實驗室
  • 其他

6. 多種癌症早期檢測 (MCED) 市場：區域估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的近期趨勢及影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Illumina, Inc. (GRAIL, LLC)
    • GRAIL, Inc.
    • Exact Sciences Corporation
    • FOUNDATION MEDICINE, INC.
    • AnchorDx
    • Guardant Health
    • Burning Rock Biotech Limited
    • GENECAST
    • Beijing Lyman Juntai International Medical Technology Development Co.
    • Freenome Holdings, Inc.
    • Elypta AB
Product Code: GVR-4-68039-966-1

Multi Cancer Early Detection Market Growth & Trends:

The global multi cancer early detection market size is expected to reach USD 2.86 billion by 2030, registering a CAGR of 17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The need for providing effective ways to detect cancer at an early stage so that the right treatment can be given and the rising prevalence of cancer and multiple forms are expected to fuel the growth of the market. The requirement for early detection diagnostics, which facilitates simple disease management and subsequently lowers the death rate, drives the overall market.

Multi cancer early detection (MCED) tests are designed to find tumors in the body even when a patient is asymptomatic. To determine whether there is a high probability that a person has cancer, they simultaneously evaluate several signals. Although numerous tests are being developed to detect cancer at an early stage, the first MCED screening test was just recently made available in the U.S. as a lab-developed test. For instance, in July 2022, GRAIL's Galleri was made available as an LDT at Mercy, St. Louis. Furthermore, MCED screening tests are being developed by Exact Sciences and Freenome, and GRAIL's Galleri test is being marketed without payer coverage with the claim that it can detect up to fifty different forms.

Studies show that MCED tests have a higher sensitivity for detecting later-stage or advanced than for detecting earlier stages, which are more treatable and occasionally curable. Additionally, it was found that the tests were highly specific, which made it extremely unlikely that they would give a positive result for someone who did not have cancer. To meet the demand for early diagnosis, ongoing research is still being done in the field of developing MCED.

The major players in the market assert that they can identify as few as two or three different cancer types or as many as fifty. They are focusing on the growth and development of these screening tests and faster commercialization. For instance, in December 2020, Singlera Genomics raised $150 million in Series B funding for the development, marketing, and promotion of its MCED tests. GRAIL launched a pilot project with Point32Health, making Point32Health the first commercial plan for health to include MCED tests.

Multi Cancer Early Detection Market Report Highlights:

  • The gene panel, LDT, & others segment led the market and accounted for a share of 91.28% in 2024. The growth of the segment is attributed to the non-requirement of FDA approval for the utilization of LDT in diagnostic laboratories.
  • The liquid biopsy segment is anticipated to grow at the fastest CAGR over the forecast period. The growth of this segment is attributed to the increasing number of players receiving funding from investors for the development of new tests.
  • The hospitals end-use segment led the market with a share of 48.44% in 2024. This is attributed to the growing preference of hospitals for care due to the availability of various services under one roof.
  • Asia Pacific multi cancer early detection market is anticipated to witness the fastest CAGR over the forecast period due to a significantly improving healthcare infrastructure, a growing population, and a rising number of local companies entering the market

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Multi Cancer Early Detection (MCED) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Extensive R&D for the development of MCED
      • 3.2.1.3. Need to develop diagnostic options that can detect cancer at an early stage
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Collection of adequate safety and efficacy data for regulatory approval
  • 3.3. Multi Cancer Early Detection (MCED) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Multi Cancer Early Detection (MCED) Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Multi Cancer Early Detection (MCED) Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Liquid Biopsy
    • 4.5.1. Liquid biopsy market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Gene Panel, LDT, and Others
    • 4.6.1. Gene panel, LDT, and others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Multi Cancer Early Detection (MCED) Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Multi Cancer Early Detection (MCED) Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Hospitals
    • 5.5.1. Hospitals market estimates and forecasts 2018 - 2030 (USD million)
  • 5.6. Diagnostic Laboratories
    • 5.6.1. Diagnostic laboratories market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Other
    • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Multi Cancer Early Detection (MCED) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Illumina, Inc. (GRAIL, LLC)
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. GRAIL, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Exact Sciences Corporation
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. FOUNDATION MEDICINE, INC.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. AnchorDx
      • 7.3.8.1. Company overview
      • 7.3.8.2. Product benchmarking
      • 7.3.8.3. Strategic initiatives
    • 7.3.9. Guardant Health
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Burning Rock Biotech Limited
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. GENECAST
      • 7.3.11.1. Company overview
      • 7.3.11.2. Product benchmarking
      • 7.3.11.3. Strategic initiatives
    • 7.3.12. Beijing Lyman Juntai International Medical Technology Development Co.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Product benchmarking
      • 7.3.12.3. Strategic initiatives
    • 7.3.13. Freenome Holdings, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Product benchmarking
      • 7.3.13.3. Strategic initiatives
    • 7.3.14. Elypta AB
      • 7.3.14.1. Company overview
      • 7.3.14.2. Product benchmarking
      • 7.3.14.3. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 15 Germany multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 17 UK multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 19 France multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 21 Italy multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 23 Spain multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 25 Denmark multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 27 Sweden multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 29 Norway multi cancer early detection market, by end use, 2018 - 2030 (USD Million)Asia Pacific multi cancer early detection market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 31 China multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 32 China multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 36 India multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 37 South Korea multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 38 South Korea multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Australia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 40 Australia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 45 Latin America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Brazil multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 47 Brazil multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Argentina multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 49 Argentina multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 50 MEA multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 51 MEA multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 52 MEA multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Africa multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 54 South Africa multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 57 UAE multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 58 UAE multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Kuwait multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait multi cancer early detection market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Multi cancer early detection market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Multi cancer early detection market driver impact
  • Fig. 20 Multi cancer early detection market restraint impact
  • Fig. 21 Multi cancer early detection market strategic initiatives analysis
  • Fig. 22 Multi cancer early detection market: Type movement analysis
  • Fig. 23 Multi cancer early detection market: Type outlook and key takeaways
  • Fig. 24 Liquid biopsy market estimates and forecast, 2018 - 2030
  • Fig. 25 Gene panel, LDT, & others estimates and forecast, 2018 - 2030
  • Fig. 26 Multi cancer early detection market: End Use movement Analysis
  • Fig. 27 Multi cancer early detection market: End Use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 29 Diagnostic laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 30 Others market estimates and forecasts,2018 - 2030
  • Fig. 31 Global multi cancer early detection market: Regional movement analysis
  • Fig. 32 Global multi cancer early detection market: Regional outlook and key takeaways
  • Fig. 33 Global multi cancer early detection market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 53 Europe
  • Fig. 54 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 55 UK
  • Fig. 56 UK market estimates and forecasts, 2018 - 2030
  • Fig. 57 Germany
  • Fig. 58 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 59 France
  • Fig. 60 France market estimates and forecasts, 2018 - 2030
  • Fig. 61 Italy
  • Fig. 62 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 63 Spain
  • Fig. 64 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 65 Denmark
  • Fig. 66 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 67 Sweden
  • Fig. 68 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 69 Norway
  • Fig. 70 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 71 Asia Pacific
  • Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 73 China
  • Fig. 74 China market estimates and forecasts, 2018 - 2030
  • Fig. 75 Japan
  • Fig. 76 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 77 India
  • Fig. 78 India market estimates and forecasts, 2018 - 2030
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 101 Market share of key market players - Multi cancer early detection market